MAIA Biotechnology
MAIA
20 hedge funds and large institutions have $1.5M invested in MAIA Biotechnology in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 5 closing their positions.
56% more capital invested
Capital invested by funds: $964K → $1.5M (+$539K)
1.47% less ownership
Funds ownership: 4.77% → 3.3% (-1.5%)
9% less funds holding
Funds holding: 22 → 20 (-2)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$161K |
| 2 |
VF
Virtu Financial
New York
|
+$48.7K |
| 3 |
Jane Street
New York
|
+$37.6K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$13.1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$153K |
| 2 |
Renaissance Technologies
New York
|
-$138K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$50.6K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$45K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$28K |
MAIA Hedge Fund Activity: Q1 2024 in Review
20 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in MAIA Biotechnology (MAIA) for Q1 2024, worth a combined $1.5M — up 56% from $964K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of MAIA and 3 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $161K. The largest seller was Sabby Management, exiting entirely with an estimated $153K sold.
- 20 institutional investors held MAIA Biotechnology (MAIA) as of Q1 2024, down from 22 in Q4 2023.
- Funds reported $1.5M of MAIA Biotechnology stock for Q1 2024, up 56% quarter-over-quarter.
- 3 funds opened new MAIA Biotechnology positions in Q1 2024 and 5 closed out, a net change of -2 holders.
- The largest MAIA Biotechnology buyer in Q1 2024 was Vanguard Group, an estimated $161K added.
- The largest MAIA Biotechnology seller in Q1 2024 was Sabby Management, an estimated $153K sold.
Based on aggregated 13F filings for Q1 2024.